Indeed this vaccine platform has reliably induced antibody immunogenicity against the MSP1 and AMA1 blood-stage malaria antigens in mice, rabbits, rhesus macaques and humans [21], [22], [25], [26], [28], and further studies in mice and rhesus macaques have indicated that combining the protein and viral vectored subunit vaccine platforms may allow for the induction of even higher antibody titers [26], [46], [55]. The gene discussed is ATAD1; the disease is malaria.